Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioCryst Pharmaceuticals, Inc. (BCRX) had Revenue of $218.25M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$218.25M
Net Income	$78.39M
Cost of Goods Sold	$3.84M
Gross Profit	$214.41M
Operating Expenses	$119.78M
Operating Income	$98.47M
Non-Operating Income/Expense	$-18.99M
Pre-Tax Income	$79.47M
Normalized Pre-Tax Income	$79.47M
Income after Taxes	$78.39M
Income from Continuous Operations	$78.39M
Consolidated Net Income/Loss	$78.39M
Normalized Income after Taxes	$78.39M
EBIT	$98.47M
EBITDA	$98.76M
Weighted-Average Shares Outstanding (Basic)	254.48M
Weighted-Average Shares Outstanding (Diluted)	265.17M
Earnings per Share (EPS) (Basic)	$0.31
Earnings per Share (EPS) (Diluted)	$0.30
Balance Sheet Financials
Current Assets	$484.68M
Property, Plant, and Equipment	$9.06M
Long-Term Assets	$73.17M
Total Assets	$557.85M
Current Liabilities	$208.85M
Long-Term Debt	$779.23M
Long-Term Liabilities	$803.29M
Total Liabilities	$1.01B
Common Equity	$-454.29M
Tangible Shareholders Equity	$-454.29M
Shareholders Equity	$-454.29M
Common Shares Outstanding	255.26M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$42.55M
Cash Flow from Investing Activities	$-378.80M
Cash Flow from Financial Activities	$401.40M
Beginning Cash	--
End Cash	$65.05M
Increase/Decrease in Cash	$65.05M
Stock-Based Compensation	$30.72M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.32
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.40
Debt to Equity Ratio	-1.85
Gross Margin	98.24%
Operating Margin	45.12%
EBIT Margin	45.12%
EBITDA Margin	--
Pre-Tax Profit Margin	36.41%
Profit Margin	35.92%
Free Cash Flow	$41.94M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.39
Inventory Turnover	0.63
Receiveable Turnover	1.97
Days Sales in Receivables	45.67
Return on Equity	-17.26%
Return on Tangible Equity	-17.26%
Return on Assets	14.05%
Return on Investments	24.13%
Book Value Per Share	$-1.78
Free Cash Flow per Share	$0.16
Operating Cash Flow per Share	$0.16

Data from Zacks Investment Research, Inc.